CANDEL THERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
CANDEL THERAPEUTICS, INC. (CADL) reported Capital Expenditures Incurred but Not yet Paid of $68.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was $29.00K.
- CANDEL THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $39.00K, a 143.75% increase year-over-year.
- CANDEL THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $7.00K.
- CANDEL THERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $112.00K, a 3633.33% increase year-over-year.
- CANDEL THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $132.00K.
- CANDEL THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $69.00K.
- CANDEL THERAPEUTICS, INC. capital expenditures incurred but not yet paid for fiscal 2020 was $977.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $68.00K 10-Q · filed 2026-08-13 | $75.00K derived: sum of 3 quarters · filed 2026-08-13 | $187.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $39.00K 10-Q · filed 2026-05-14 | $46.00K derived: sum of 2 quarters · filed 2026-05-14 | $158.00K derived: sum of 3 quarters · filed 2026-05-14 | $155.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $119.00K derived: sum of 2 quarters · filed 2026-03-12 | $116.00K derived: sum of 3 quarters · filed 2026-08-13 | $132.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $109.00K derived: sum of 2 quarters · filed 2026-08-13 | $125.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $13.00K 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $16.00K 10-Q · filed 2026-05-14 | |||
| 2024-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.00K derived: sum of 2 quarters · filed 2025-11-13 | $3.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2023-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$47.00K derived: sum of 2 quarters · filed 2024-11-14 | $19.00K 10-Q · filed 2024-11-14 | -$173.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $16.00K 10-Q · filed 2024-08-13 | -$176.00K derived: sum of 3 quarters · filed 2024-08-13 | -$169.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $66.00K 10-Q · filed 2024-05-14 | -$126.00K derived: sum of 2 quarters · filed 2024-05-14 | -$119.00K derived: sum of 3 quarters · filed 2024-05-14 | -$286.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$185.00K derived: sum of 2 quarters · filed 2024-03-28 | -$352.00K derived: sum of 3 quarters · filed 2024-03-28 | $69.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$160.00K derived: sum of 2 quarters · filed 2023-11-09 | $261.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$167.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $254.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $421.00K 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.33M derived: sum of 2 quarters · filed 2022-08-05 | $523.00K 10-Q · filed 2021-11-12 | $1.43M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-06-30 | -$238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $1.61M 10-Q · filed 2022-08-05 | $2.52M derived: sum of 3 quarters · filed 2022-08-05 | $2.58M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $1.85M 10-Q · filed 2022-05-12 | $2.76M derived: sum of 2 quarters · filed 2022-05-12 | $2.81M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $908.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $963.00K derived: sum of 2 quarters · filed 2022-03-29 | $977.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $69.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $14.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |